Adverse Event Management

CRS is a common but manageable toxicity of CAR T-cell therapy and bispecific antibodies. Learn strategies to identify and manage this adverse effect.

Paolo Tarantino, MD, PhD, discusses ADC structure, toxicity, and nursing consideration for the treatment of patients with breast cancer.

Nurse practitioner Beth Faiman outlines nursing strategies to monitor, assess, and manage toxicities associated with talquetamab in multiple myeloma.

A nurse-led clinic to aid in patient-reported symptom burden had high patient satisfaction.

Melissa Rikal, MSN, FNP-BC, AOCNP, explained that adverse effects are common among the available antibody-drug conjugates in breast cancer.

Oncology nurses play a key role in monitoring, managing, and personalizing CDK4/6 inhibitor treatment to minimize toxicities and protect quality of life, according to Courtney Moore, APRN, FNP-C, OCN.

Experts outline AE risks—including ICANS, CRS, HLH—as T-cell engager use expands, highlighting the crucial role of nurses and APPs.

For patients with HR-positive breast cancer, adverse effects vary by CDK4/6 inhibitor, says Courtney Moore, APRN, FNP-C, OCN.

Hope S. Rugo, MD, FASCO, outlined the top considerations for nurses managing toxicities related to PI3K and AKT inhibitors in patients with breast cancer.

Adding aprepitant to chemotherapy was linked to longer survival in patients with non-luminal breast cancers, especially triple-negative breast cancer.

2025 ICE-T Conference presenters explain what nurses and APPs should take into account as immune cell effector therapies become more widely used.

Hope S. Rugo, MD, FASCO, emphasized the importance of educating patients about proactive rash and diarrhea management while taking PI3K/AKT inhibitors.

Oncology nurses can assess patients’ risk factors and advocate for preventive strategies that protect kidney function during cisplatin therapy.

If patients with breast cancer have hyperglycemia or symptoms of it at home, a short break from capivasertib may be required, according to Hope Rugo, MD.

New therapies in breast cancer, particularly ADCs, present unique safety profiles for nurses to be aware of, according to Erika Hamilton, MD.

Getting to the root of patients’ issues can provide support for their cancer journey through accessible means, says Heather Jackson, PhD, APRN, FNP-BC, NEA-BC, FAA-NP.

Those who took olanzapine reported higher levels of satisfaction than patients on placebo.

Step-up dosing with remote monitoring resulted in 47% of patients receiving bispecific antibodies remaining outpatient, even in cases of CRS.

Volumetric PET biomarkers may help predict risk of toxicity from CAR T-cell therapy in patients with large B-cell lymphoma, new retrospective data suggest.

Planning for adverse effects early on helps patients prepare for what lies ahead, says Michelle Kirschner, MSN, RN, ACNP, APRN-BC.

Adding danazol or erythropoiesis-stimulating agents for anemia management to a ruxolitinib regimen for myelofibrosis does not decrease treatment efficacy.

Because oncology nurses are at the forefront of patient care, they are uniquely positioned to facilitate cancer survivorship and lymphedema prevention.

Oncology nurses can play a key role in educating patients and supporting clinical trial participation for this new treatment option.

Olanzapine plus an antiemetic shows potential in preventing RINV while reducing other adverse events such as depression, appetite loss, and insomnia.

By monitoring patients’ CBC and other symptoms, nurses and advanced practice providers can spot early indicators of parkinsonism risk, per Yi Lin, MD, PhD.

COCOON skin care led to fewer or milder dermatologic symptoms with amivantamab/lazertinib vs standard care in patients with EGFR+ advanced NSCLC.

Toxicities related to Teliso-V are manageable for patients with c-Met overexpressing non-small cell lung cancer, according to Jonathan Goldman, MD.